BMN 355
Alternative Names: BMN-355Latest Information Update: 02 May 2024
Price :
$50 *
At a glance
- Originator BioMarin Pharmaceutical
- Class Antiarrhythmics; Monoclonal antibodies
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Long QT syndrome
Most Recent Events
- 24 Apr 2024 Discontinued - Preclinical for Long QT syndrome in USA (Parenteral), due to portfolio prioritization
- 07 Oct 2023 BioMarin Pharmaceutical announces intention to submit IND for long QT syndrome (BioMarin Pharmaceutical website, September 2023)
- 12 Sep 2023 Preclinical trials in Long QT syndrome in USA (Parenteral) (BioMarin Pharmaceutical pipeline, September 2023)